Security Snapshot

DIREXION SHARES ETF TRUST - DAIL HEAL BU ETF (CURE) Institutional Ownership

CUSIP: 25459Y876

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

20

Shares (Excl. Options)

111,967

Price

$112.17

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+60,240
Value change
+$6,980,817
Number of holders
20
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported price per share
$144.69
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • CURE - DIREXION SHARES ETF TRUST - DAIL HEAL BU ETF is tracked under CUSIP 25459Y876.
  • 20 institutions reported positions in Q2 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 16 to 20 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $4,711,427 to $12,527,394.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 20 institutions filings for Q2 2026.

Open SEC evidence

Security key

25459Y876

Latest holder period

Q2 2026

13F holders

20

13D/G owners

0

CIK / CUSIP context first

As of 30 Jun 2026, 20 institutional investors reported holding 111,967 shares of DIREXION SHARES ETF TRUST - DAIL HEAL BU ETF (CURE).

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 111,967 $12,527,394 +$6,980,817 $112.17 20
2026 Q1 51,726 $4,711,427 -$9,705,780 $91.57 16
2025 Q4 150,081 $16,743,058 -$582,709 $111.56 20
2025 Q3 176,977 $15,149,117 +$6,201,048 $83.52 23
2025 Q2 104,829 $8,738,642 -$2,121,036 $78.82 21
2025 Q1 119,630 $12,749,419 -$3,651,625 $106.61 21
2024 Q4 162,215 $14,967,674 +$2,061,776 $92.29 23
2024 Q3 117,641 $14,975,249 -$10,934,696 $133.18 19
2024 Q2 209,029 $24,832,086 -$619,320 $116.81 21
2024 Q1 212,892 $26,661,184 +$41,524 $125.45 23
2023 Q4 212,898 $21,651,140 +$427,610 $101.74 21
2023 Q3 211,193 $18,695,500 +$3,185,404 $88.53 20
2023 Q2 172,863 $17,292,257 +$3,960,918 $100.01 20
2023 Q1 111,129 $10,668,334 +$5,851,532 $96.00 13
2022 Q4 48,370 $5,550,191 -$3,013,993 $114.76 20
2022 Q3 75,620 $6,384,394 +$4,299,088 $84.44 18
2022 Q2 24,736 $2,549,132 -$6,683,921 $103.08 17
2022 Q1 82,130 $10,714,439 -$2,026,081 $130.45 22
2021 Q4 93,191 $13,512,085 +$5,665,143 $144.96 20
2021 Q3 59,622 $6,415,296 +$3,553,188 $107.43 19
2021 Q2 26,189 $2,785,000 -$5,481,399 $104.58 14
2021 Q1 90,189 $7,533,644 -$4,130,827 $83.51 15
2020 Q4 144,746 $11,147,104 +$4,022,795 $77.00 17
2020 Q3 92,309 $5,870,731 -$7,543,034 $63.02 13
2020 Q2 215,776 $11,724,759 +$1,931,782 $54.33 15
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .